Skip to main content

Test Price

2,800 AED

โœ… Home Collection Available

GJB1 Gene (Dejerine-Sottas Disease) Next-Generation Sequencing Genetic Test in UAE

Executive Summary & Core Metrics

  • โœ“ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing
  • โœ“ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy
  • โœ“ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation
  • โœ“ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731

Test Overview & Methodology

This next-generation sequencing test analyses the entire coding region of the GJB1 gene to identify pathogenic variants causing Dejerine-Sottas disease, a severe early-onset hereditary peripheral neuropathy. Early molecular confirmation enables personalised neurological care and informed family decisions.

Feature Our Test (DHA-Licensed) Closest Alternative (External Panel)
Methodology NGS full gene sequencing Targeted mutation analysis / limited panel
Sensitivity 99.9% (including deep intronic variants) ~85% (misses novel/rare variants)
Turnaround 4 โ€“ 5 weeks 6 โ€“ 8 weeks
Regulatory DHA / MOHAP compliant, ISO 9001:2015 Variable

Physician Insight & Safety Protocols

From Lina Osama Zaki Quteineh โ€” Consultant Medical Genetics (DHA: 9294403): โ€œGenetic testing for Dejerine-Sottas disease provides clarity in a condition often mistaken for other neuromuscular disorders. Our results integrate comprehensive clinical correlation so that each family receives a roadmap โ€” not just a raw data dump. You are not alone in this journey; our multidisciplinary team supports you from sample collection to interpretation.โ€

Important Clinical Advisory

โš ๏ธ Medication Warning:

Do not discontinue prescribed medication without consulting your doctor. Genetic test results should always be discussed with your treating neurologist before any change in therapy.

Safety Exclusion Criteria & ER Red Flags

Home Collection Exclusion:

  • Uncontrolled bleeding disorder or therapeutic anticoagulation
  • Active severe skin infection at puncture site
  • Acute febrile illness > 38.5ยฐC
  • Patient unable to provide informed consent (for minors, guardian consent required under UAE law)

Seek Emergency Care if:

  • Sudden worsening of limb weakness or gait instability
  • Respiratory difficulty or chest infection symptoms
  • Severe, unexplained pain or autonomic dysfunction
  • Loss of consciousness

Patient FAQ & Clinical Guidance

1. What is the GJB1 gene and how does it relate to Dejerine-Sottas disease?

Key Insight: A GJB1 gene mutation leads to connexin 32 deficiency, disrupting myelin in peripheral nerves and causing progressive neuropathy. This test identifies disease-causing variants, enabling definitive diagnosis and differentiation from other Charcot-Marie-Tooth subtypes.

2. How accurate is this NGS test for Dejerine-Sottas disease compared to older methods?

Key Insight: With 99.9% analytical sensitivity, our NGS approach detects >99% of known GJB1 mutations and many deep intronic variants missed by single-gene Sanger sequencing. A negative result therefore significantly reduces the likelihood of GJB1-related disease, narrowing the diagnostic path.

3. What do I need to do before the blood draw and will insurance cover the cost?

Key Insight: A genetic counselling session to draw a detailed pedigree is highly recommended prior to testing; this forms part of our pre-service. Most UAE insurers cover medically necessary carrier/pre-symptomatic testing for hereditary neuropathies โ€” our team verifies your policy via WhatsApp before collection.

UAE Regulatory & Data Privacy Adherence

Data Protection & Compliance

This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed exclusively within the UAE. Clinical testing safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory operations are certified under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).

Clinical & Logistical Metadata

Test Name GJB1 Gene (Dejerine-Sottas Disease) Next-Generation Sequencing
Price (AED) 2,800
Turnaround Time 4 โ€“ 5 weeks
Sample Type / Matrix Peripheral whole blood (3-5 mL in EDTA tube)
Methodology Used Next-Generation Sequencing (NGS) โ€“ full gene coding region + flanking intronic regions
ICD-10-CM Code G60.0
LOINC Code 81523-0
DHA Facility License & Laboratory Address License No. 1143 ยท Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE ยท DNA Labs UAE

ุฏุนู… ุซู†ุงุฆูŠ ุงู„ู„ุบุฉ ู…ุชุงุญ

ุงู„ุชุญู‚ู‚ ู…ู† ุงู„ุชุบุทูŠุฉ ุงู„ุชุฃู…ูŠู†ูŠุฉ

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

ุชูˆู‚ู ุนู† ุงู„ุชุฎู…ูŠู†. ุฃุฑุณู„ ุตูˆุฑุฉ ู…ู† ุจุทุงู‚ุฉ ุงู„ุชุฃู…ูŠู† ูˆูˆุตูุฉ ุงู„ุทุจูŠุจ ุฅู„ู‰ ูุฑูŠู‚ ุงู„ุชุญู‚ู‚ ุงู„ู…ุนุชู…ุฏ ู…ู† ู‡ูŠุฆุฉ ุงู„ุตุญุฉ ุจุฏุจูŠ ุนุจุฑ ุงู„ูˆุงุชุณุงุจ. ุงุญุตู„ ุนู„ู‰ ุชุญุฏูŠุซ ุงู„ุญุงู„ุฉ ููŠ ุฏู‚ุงุฆู‚.

โœ… DHA Certified โœ… ISO 15189 โœ… HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

๐Ÿ…

ISMS 27001:2022

๐Ÿ“‹

ISO Accredited

๐Ÿ”’

HIPAA

All reports reviewed by DHA-Certified physicians